Efavirenz--still first-line king? (Q81636133)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Efavirenz--still first-line king? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

Brookie M Best

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Miguel Goicoechea

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

965-972

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe

10 January 2020

cites work

1 reference

12 December 2020

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis

1 reference

12 December 2020

Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

1 reference

12 December 2020

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

1 reference

12 December 2020

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

12 December 2020

Efavirenz use during pregnancy and for women of child-bearing potential

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs

1 reference

12 December 2020

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

12 December 2020

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

1 reference

12 December 2020

A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

1 reference

12 December 2020

HIV drug resistance surveillance: summary of an April 2003 WHO consultation

1 reference

12 December 2020

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

1 reference

12 December 2020

Myelomeningocele in a child with intrauterine exposure to efavirenz.

1 reference

12 December 2020

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

1 reference

12 December 2020

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients

1 reference

12 December 2020

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

1 reference

12 December 2020

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort

1 reference

12 December 2020

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

1 reference

12 December 2020

Genetic correlates of efavirenz hypersusceptibility

1 reference

12 December 2020

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

1 reference

12 December 2020

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

1 reference

12 December 2020

Higher efavirenz plasma levels correlate with development of insomnia

1 reference

12 December 2020

Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance

1 reference

12 December 2020

1 reference

12 December 2020

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

1 reference

12 December 2020

Identifiers

DOI

10.1517/17425255.4.7.965

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624683%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

PubMed publication ID

18624683

1 reference